Table 1. Clinicopathologic Characteristics of Validation Cohort.
| Variable | Average | Number (%) |
|---|---|---|
| Age | 58.9 | |
| PSA | 10.24 | |
| Tumor Volume (cc) | 0.19 | |
| Gleason score* | ||
| 6 | 18 (32.7%) | |
| 7 | 30 (54.5%) | |
| 8 | 3 (5.5%) | |
| 9 | 4 (7.3%) | |
| Stage | ||
| II | 35 (62.5%) | |
| III | 11 (19.6%) | |
| IV | 10 (17.9%) | |
| Metastatic | ||
| No | 46 (82.1%) | |
| Yes | 10 (17.9%) | |
| Extraprostatic Extension | ||
| No | 39 (69.6%) | |
| Yes | 17 (30.4%) | |
| SV Involvement | ||
| No | 44 (80%) | |
| Yes | 11 (20%) | |
| Biochemical Recurrence** | ||
| No | 31 (70.5%) | |
| Yes | 13 (29.5%) | |
* One patient missing clinical data
**44 Patients with complete biochemical recurrence follow-up